Table 1 Summary of MIC, gene mutation, MLST, doubling time, cell-wall thickness, cytochrome c uptake and L-PG content on the isolates from DAP treatment patients.
Patient | Strain | DAP MIC | VCM MIC | MLST | Mutation in | Doubling time (min) | Cell wall thickness (nm) | Cytochrome c uptake (%)g | L-PG content (%)h | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
mg/L | Ratioa | mg/L | Ratioa | mprF | Others | |||||||
Cross-reduced susceptibility group (to DAP and VCM) | ||||||||||||
A | A-1 | 0.38 | 1.00 | 1.5 | 1.00 | 764 | –b | – | 26.6 | 23.18 ± 2.50 | 100 | 100 |
A-2 | 1.5 | 3.95 | 2 | 1.33 | 764 | T345I | – | 27.0 | 24.40 ± 1.72 | 73.27 ± 6.79* | 177.20 ± 18.47* | |
B | B-1 | 0.19 | 1.00 | 1.5 | 1.00 | 764 | – | – | 30.0 | 23.28 ± 2.73 | 100 | 100 |
B-2 | 1.5 | 7.89 | 2 | 1.33 | 764 | L776S | B1_1709 (N31_fs)c | 30.7 | 22.41 ± 1.58 | 78.75 ± 6.83** | 128.86 ± 10.58* | |
C | C-1 | 0.5 | 1.00 | 2 | 1.00 | 764 | – | – | 29.5 | 24.28 ± 2.00 | 100 | 100 |
C-3 | 1.5 | 3.00 | 3 | 1.50 | 764 | A475P | – | 30.2 | 22.17 ± 1.86 | 71.45 ± 4.51** | 147.52 ± 18.09* | |
C-4 | 3 | 6.00 | 3 | 1.50 | 764 | L459_H466 del | – | 30.9 | 23.17 ± 2.32 | 70.65 ± 11.63* | 140.48 ± 11.44* | |
D | D-1 | 0.25 | 1.00 | 1.5 | 1.00 | 1 | – | – | 32.8 | 20.60 ± 2.77 | 100 | 100 |
D-2 | 2 | 8.00 | 2 | 1.33 | 1 | L826F | ir-1, ir-2d | 27.6 | 19.86 ± 1.80 | 52.37 ± 15.09* | 144.14 ± 12.20* | |
E | E-1 | 0.25 | 1.00 | 1 | 1.00 | 764 | – | – | 32.6 | 25.30 ± 2.46 | 100 | 100 |
E-2 | 1.5 | 6.00 | 1.5 | 1.50 | 764 | L826F | – | 36.2 | 23.64 ± 2.67 | 61.79 ± 3.30** | 166.21 ± 24.86* | |
F | F-1 | 0.25 | 1.00 | 0.75 | 1.00 | 764 | – | – | 33.3 | 24.89 ± 2.39 | 100 | 100 |
F-2 | 2 | 8.00 | 1.5 | 2.00 | 764 | L826F | agrA(T210I), F1_0943(A363T) | 36.5 | 25.86 ± 2.15 | 71.98 ± 4.81* | 124.00 ± 12.49* | |
G | G-1 | 0.5 | 1.00 | 1 | 1.00 | 2809 | – | – | 32.2 | 30.02 ± 2.32 | 100 | 100 |
G-2 | 1.5 | 3.00 | 1.5 | 1.50 | 2809 | T345A | ir | 31.4 | 29.72 ± 2.15 | 45.99 ± 2.14** | 158.88 ± 26.37* | |
H | H-1 | 0.75 | 1.00 | 2 | 1.00 | 5 | – | – | 27.1 | 23.31 ± 1.84 | 100 | 100 |
H-3 | 0.5 | 0.67 | 2 | 1.00 | 5 | – | hisF(G207_del), H1_0704(C241Y) | 25.9 | NDe | 92.05 ± 4.73 | 89.62 ± 7.58 | |
H-5 | 3 | 4.00 | 3 | 1.50 | 5 | L291I | hisF(G207_del), H1_0704(C241Y) | 26.6 | 22.92 ± 2.35 | 78.46 ± 0.77** | 155.3 ± 13.74* | |
H-5(mprF_H-1) | 0.5 | 1.00 | 2 | 1.00 | 5 | – | hisF(G207_del), H1_0704(C241Y) | ND | ND | 100 | 100 | |
H-3(mprF_H-5) | 3 | 6.00 | 3 | 1.50 | 5 | L291I | hisF(G207_del), H1_0704(C241Y) | ND | ND | 69.26 ± 7.81* | 149.26 ± 21.91* | |
I | I-2 | 0.75 | 1.00 | 2 | 1.00 | NT | – | – | 27.0 | 22.11 ± 1.83 | 100 | 100 |
I-3 | 3 | 4.00 | 3 | 1.50 | NT | W424R | – | 33.8 | 25.55 ± 2.92** | 68.88 ± 5.90* | 165.51 ± 12.12* | |
J | J-1 | 0.38 | 1.00 | 1.5 | 1.00 | 764 | – | – | 27.1 | 23.44 ± 1.37 | 100 | 100 |
J-3 | 1.5 | 3.95 | 2 | 1.33 | 764 | L341S | – | 30.1 | 23.40 ± 1.63 | 73.32 ± 3.19** | 119.66 ± 7.16* | |
L | L-1 | 0.25 | 1.00 | 1.5 | 1.00 | 380 | – | – | 26.5 | 22.12 ± 1.80 | 100 | 100 |
L-2 | 2 | 8.00 | 2 | 1.33 | 380 | S337L | L1_0548(T134I) | 29.9 | 22.24 ± 1.29 | 69.99 ± 9.15* | 116.96 ± 4.30* | |
Reduced susceptibility to only DAP group | ||||||||||||
K | K-1 | 0.38 | 1 | 1.5 | 1 | 764 | – | lacF(trunc)f | 24.7 | 21.50 ± 1.82 | 100 | 100 |
K-2 | 2 | 5.26 | 1.5 | 1.00 | 764 | – | lacF(H41) | 27.1 | 21.15 ± 1.75 | 122.16 ± 1.00* | 55.01 ± 15.16** | |
